FDA — authorised 29 December 1981
- Application: NDA050545
- Marketing authorisation holder: WYETH PHARMS INC
- Local brand name: PIPRACIL
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Pipracil in United States
FDA authorised Pipracil on 29 December 1981
Marketing authorisations
FDA — authorised 13 October 1987
- Application: ANDA062750
- Marketing authorisation holder: WYETH PHARMS INC
- Local brand name: PIPRACIL
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 24 February 1998
- Application: NDA050750
- Marketing authorisation holder: BAXTER HLTHCARE CORP
- Local brand name: ZOSYN IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 3 April 2025
- Application: NDA206056
- Marketing authorisation holder: B BRAUN MEDICAL
- Local brand name: PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
- Indication: POWDER — INTRAVENOUS
- Status: approved
FDA
- Status: approved
Pricing & reimbursement
- annual_list: USD 80000.00 per year
Pipracil in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Pipracil approved in United States?
Yes. FDA authorised it on 29 December 1981; FDA authorised it on 13 October 1987; FDA authorised it on 24 February 1998.
Who is the marketing authorisation holder for Pipracil in United States?
WYETH PHARMS INC holds the US marketing authorisation.
What does Pipracil cost in United States?
annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.